BRPI0909630A2 - suspensões de triancinolona acetonida altamente floculada de baixa viscosidade para injeção intravitreal - Google Patents

suspensões de triancinolona acetonida altamente floculada de baixa viscosidade para injeção intravitreal

Info

Publication number
BRPI0909630A2
BRPI0909630A2 BRPI0909630A BRPI0909630A BRPI0909630A2 BR PI0909630 A2 BRPI0909630 A2 BR PI0909630A2 BR PI0909630 A BRPI0909630 A BR PI0909630A BR PI0909630 A BRPI0909630 A BR PI0909630A BR PI0909630 A2 BRPI0909630 A2 BR PI0909630A2
Authority
BR
Brazil
Prior art keywords
suspensions
low viscosity
intravitreal injection
viscosity highly
highly flocculated
Prior art date
Application number
BRPI0909630A
Other languages
English (en)
Inventor
Bhagwati P Kabra
Ruma Sarkar
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of BRPI0909630A2 publication Critical patent/BRPI0909630A2/pt
Publication of BRPI0909630B1 publication Critical patent/BRPI0909630B1/pt
Publication of BRPI0909630B8 publication Critical patent/BRPI0909630B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0909630A 2008-03-11 2009-03-10 composição em suspensão aquosa particularmente adequada para injeção dentro do olho BRPI0909630B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3545908P 2008-03-11 2008-03-11
US61/035,459 2008-03-11
PCT/US2009/036652 WO2009114521A1 (en) 2008-03-11 2009-03-10 Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection

Publications (3)

Publication Number Publication Date
BRPI0909630A2 true BRPI0909630A2 (pt) 2015-09-22
BRPI0909630B1 BRPI0909630B1 (pt) 2019-03-26
BRPI0909630B8 BRPI0909630B8 (pt) 2021-05-25

Family

ID=40548758

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909630A BRPI0909630B8 (pt) 2008-03-11 2009-03-10 composição em suspensão aquosa particularmente adequada para injeção dentro do olho

Country Status (22)

Country Link
US (3) US8128960B2 (pt)
EP (1) EP2262506B1 (pt)
JP (1) JP5581227B2 (pt)
KR (1) KR101555293B1 (pt)
CN (1) CN101959519B (pt)
AR (1) AR070824A1 (pt)
AU (1) AU2009223649B2 (pt)
BR (1) BRPI0909630B8 (pt)
CA (1) CA2717605C (pt)
CL (1) CL2009000573A1 (pt)
DK (1) DK2262506T3 (pt)
ES (1) ES2471122T3 (pt)
HK (1) HK1146464A1 (pt)
MX (1) MX2010009974A (pt)
PL (1) PL2262506T3 (pt)
PT (1) PT2262506E (pt)
RU (1) RU2481842C2 (pt)
SI (1) SI2262506T1 (pt)
TW (1) TWI468165B (pt)
UY (1) UY31699A1 (pt)
WO (1) WO2009114521A1 (pt)
ZA (1) ZA201005839B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
ES2471122T3 (es) * 2008-03-11 2014-06-25 Alcon Research, Ltd. Suspensiones de acet�nido de triamcinolona altamente floculadas y de baja viscosidad para inyección intrav�trea
JP2012513393A (ja) * 2008-12-22 2012-06-14 アルコン リサーチ， リミテッド 眼の後区に、有効濃度の活性剤を送達するための、眼の局部に用いる溶液の組成物
EP3520749A1 (en) 2010-10-15 2019-08-07 Clearside Biomedical, Inc. Device for ocular access
CN102008488B (zh) * 2010-11-24 2012-10-10 广州固志医药科技有限公司 一种曲安奈德眼用制剂及其制备方法
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
MX2015005839A (es) * 2012-11-08 2015-12-17 Clearside Biomedical Inc Metodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
CN105246529B (zh) 2013-05-03 2019-06-14 科尼尔赛德生物医学公司 用于眼部注射的设备和方法
WO2014197317A1 (en) 2013-06-03 2014-12-11 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
JP2017524419A (ja) 2014-06-20 2017-08-31 クリアサイド バイオメディカル，インコーポレイテッド 薬剤送達のための挿入深さを制御するための可変径カニューレ及び方法
US9694145B1 (en) 2016-03-29 2017-07-04 Joseph Onorato Auto-injector systems and method for delivering cyst medication on demand
WO2017192565A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
CN110177527B (zh) 2016-08-12 2022-02-01 科尼尔赛德生物医学公司 用于调节药剂递送用针的插入深度的装置和方法
WO2018204515A1 (en) 2017-05-02 2018-11-08 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
AU2019207515A1 (en) 2018-01-10 2020-07-30 Eye Co Pty Ltd Medical device and pharmaceutical composition for treatment of an eye disease or condition
USD893715S1 (en) 2018-11-06 2020-08-18 Joseph Onorato Measurement guide for a cyst, lesion or skin disorder
US20220211618A1 (en) * 2019-04-16 2022-07-07 Clearside Biomedical, Inc. Injectable triamcinolone formulations
US10814001B1 (en) * 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
CN114010593A (zh) * 2021-11-23 2022-02-08 莱默(北京)药业科技有限公司 一种曲安奈德混悬注射液及制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962430A (en) * 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
US4370325A (en) * 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4432964A (en) * 1981-08-24 1984-02-21 Alza Corporation Topical composition containing steroid in two forms released independently from polymeric carrier
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
US5770589A (en) 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
WO1996020712A1 (en) 1994-12-30 1996-07-11 American Home Products Corporation Clear non-alcoholic hydrocortisone solutions
NZ509797A (en) 1998-07-10 2003-11-28 Univ Sydney Prophylactic treatments of neovascularisation in macular degeneration using a steroid
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
AUPQ496500A0 (en) 2000-01-06 2000-02-03 University Of Sydney, The Kit
US6395294B1 (en) 2000-01-13 2002-05-28 Gholam A. Peyman Method of visualization of the vitreous during vitrectomy
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
EP1312356B1 (en) * 2000-08-25 2012-10-17 Senju Pharmaceutical Co., Ltd. Aqueous suspension preparations
KR20040026680A (ko) * 2001-07-09 2004-03-31 콤비네이토릭스, 인코포레이티드 염증 질환 치료용 조합
US20030129242A1 (en) 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
RU2005129276A (ru) 2003-02-20 2006-01-27 Алькон, Инк. (Ch) Применение стероидов для лечения субъектов, страдающих заболеванием глаз
US20040186084A1 (en) 2003-03-21 2004-09-23 Akorn, Inc. Triamcinolone formulations and methods for their preparation and use
CA2539023A1 (en) * 2003-09-23 2005-04-14 Alcon Inc. Triamcinolone acetonide and anecortave acetate formulations for injection
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20060141049A1 (en) 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
AU2004308973A1 (en) * 2003-12-23 2005-07-14 Alza Corporation Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
EP1706095B1 (en) 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20070225727A1 (en) 2004-05-31 2007-09-27 Keiichi Matsuhisa Transparent Tissue-Visualizng Preparation
US8246949B2 (en) 2004-10-27 2012-08-21 Aciont, Inc. Methods and devices for sustained in-vivo release of an active agent
AU2005306309A1 (en) 2004-11-17 2006-05-26 Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Steroid formulation and methods of treatment using same
EP1867334A4 (en) 2005-02-18 2009-07-15 Santen Pharmaceutical Co Ltd METHOD FOR RELIEVING OR AVOIDING A SECONDARY EFFECT OF A STEROID COMPOUND
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
ITRM20050547A1 (it) 2005-11-04 2007-05-05 Sooft Italia S R L Gel oftalmico composto da triamcinolone acetonide e da un polimero poliacrilico.
ES2471122T3 (es) * 2008-03-11 2014-06-25 Alcon Research, Ltd. Suspensiones de acet�nido de triamcinolona altamente floculadas y de baja viscosidad para inyección intrav�trea

Also Published As

Publication number Publication date
PT2262506E (pt) 2014-06-24
ES2471122T3 (es) 2014-06-25
HK1146464A1 (en) 2011-06-10
DK2262506T3 (da) 2014-06-10
JP5581227B2 (ja) 2014-08-27
UY31699A1 (es) 2009-05-29
RU2010141542A (ru) 2012-04-20
TWI468165B (zh) 2015-01-11
BRPI0909630B8 (pt) 2021-05-25
ZA201005839B (en) 2011-10-26
MX2010009974A (es) 2010-09-30
CA2717605A1 (en) 2009-09-17
EP2262506A1 (en) 2010-12-22
JP2011513492A (ja) 2011-04-28
RU2481842C2 (ru) 2013-05-20
SI2262506T1 (sl) 2014-07-31
AU2009223649A1 (en) 2009-09-17
CA2717605C (en) 2012-05-15
AR070824A1 (es) 2010-05-05
TW200940071A (en) 2009-10-01
US8211880B2 (en) 2012-07-03
US20120115829A1 (en) 2012-05-10
CN101959519B (zh) 2013-03-20
US20090233890A1 (en) 2009-09-17
WO2009114521A1 (en) 2009-09-17
KR20100127267A (ko) 2010-12-03
EP2262506B1 (en) 2014-05-07
CL2009000573A1 (es) 2010-01-04
US20120116216A1 (en) 2012-05-10
BRPI0909630B1 (pt) 2019-03-26
KR101555293B1 (ko) 2015-10-06
CN101959519A (zh) 2011-01-26
PL2262506T3 (pl) 2014-09-30
AU2009223649B2 (en) 2013-08-29
US8128960B2 (en) 2012-03-06

Similar Documents

Publication Publication Date Title
BRPI0909630A2 (pt) suspensões de triancinolona acetonida altamente floculada de baixa viscosidade para injeção intravitreal
BRPI0909855A2 (pt) "aditivos acentuadores de carga para eletretos"
BRPI0909221A2 (pt) Desordens neurodegenerativas
DK2370778T3 (da) Køretøjsstabilisering
ES1068487Y (es) Estuche para gafas de sol
TH100596B (th) ยานพาหนะแบบนั่งขี่บนอาน
ES1064798Y (es) Antirrobo para vehiculos
ES1065920Y (es) Nevera-termo para vehiculos
UA16126S (uk) Автомобіль
UA16235S (uk) Легковий автомобіль
TH106869B (th) รถยนต์
TH106872B (th) รถยนต์
TH106873B (th) รถยนต์
TH106879B (th) รถยนต์
TH106880B (th) รถยนต์
UA15123S (uk) Автомобіль
UA16124S (uk) Автомобіль
UA16125S (uk) Автомобіль
TH102825B (th) รถยนต์
UA16134S (uk) Автомобіль
UA16152S (uk) Автомобіль
UA16231S (uk) Легковий автомобіль
UA16232S (uk) Легковий автомобіль
UA16233S (uk) Легковий автомобіль
UA16234S (uk) Легковий автомобіль

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/03/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/03/2019, OBSERVADAS AS CONDICOES LEGAIS

B25A Requested transfer of rights approved

Owner name: ALCON RESEARCH, LLC (US)

B25A Requested transfer of rights approved

Owner name: ALCON INC. (CH)

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/03/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)